FDC Ltd has received a tax demand order totaling ₹156.1 million. The company is assessing the notice and its potential implications while maintaining operational continuity. Management is expected to evaluate legal options, ensure compliance, and update stakeholders on next steps, with no immediate disruption to manufacturing, distribution, or market availability.
FDC Ltd, a pharmaceutical company known for branded formulations and exports, announced receipt of a tax demand order amounting to ₹156.1 million. While the quantum is notable, the company indicated it is reviewing the order, exploring remedies, and ensuring that ongoing operations remain unaffected. Investors will watch for clarity on provisioning, appeals, and timeline.
Key highlights:
Demand amount: Tax demand quantified at ₹156.1 million.
Company stance: Evaluation of the order underway; legal and compliance responses being prepared.
Operational continuity: No immediate impact on manufacturing, distribution, or supply chain reported.
Financial implications: Potential provisioning in upcoming quarters depending on assessment and appeal outcomes.
Next steps: Possible filing of appeal/representation; further disclosures anticipated in exchange updates.
This development underscores routine regulatory scrutiny faced by listed pharma firms and the importance of timely disclosures, risk management, and stakeholder communication. Near-term focus will be on legal course, cash flow impact, and whether the company opts for partial provisioning pending resolution.
Sources: FDC Ltd, Stock exchange filing